title: [Pulmonary hypertension].
authors.affiliation: Medizinische Universität Graz. gabor.kovacs@klinikum-graz.at
authors.forename: G
authors.initials: G
authors.lastname: Kovacs
authors.forename: H
authors.initials: H
authors.lastname: Olschewski
mesh_terms: D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use; D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D004359:Drug Therapy, Combination; D061345:Early Medical Intervention; D011464:Epoprostenol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000081:Acetamides; D000959:Antihypertensive Agents; D001549:Benzamides; D010879:Piperazines; D011719:Pyrazines; D011720:Pyrazoles; D011743:Pyrimidines; D013449:Sulfonamides; C523468:selexipag; D000068877:Imatinib Mesylate; D011464:Epoprostenol; C542595:riociguat; C427248:treprostinil; C533860:macitentan